



Dec. 9, 2022

To whom it may concern

Company name : Y.A.C. HOLDINGS CO., Ltd.
(Stockcode:6298 TSE Prime)
Representative : MOMOSE Takefumi
Representative Director & President
Inquires : ITO Toshihiko
Director & Senior Managing Operating Officer,
Deputy General Manager,
Business Management Headquarter
(Tel: +81 42-546-1161)

Announcement on business alliance with Linus Biotechnology, Inc. (U.S.A.)

We are pleased to inform you that we signed Letter of Intent (hereunder call “LOI”) to enter business alliance with Linus Biotechnology, Inc. (U.S.A.) (hereunder call “LINUS”) regarding “Hair exposome analysis and biomarker development” to precise exposome medical companies of LINUS clients. The details are as follows.

1. The reason for business alliance.

- (1) We are developing and selling devices which slice soft and hard material, including biological sample.
- (2) LINUS’s exposome platform is focused on developing tools for early detection of autism spectrum disorders and providing a clinical trial platform for medical supplies development against the disorder.
- (3) LINUS paid attention to our high precise slicing and piece making technologies and concluded that those technologies would lead to epoch making innovation of medicine and medical treatment, and we expected that LINUS’s worldwide business expansion would lead our worldwide business development, therefore we decided to make business alliance.

2. Details of business alliance.

In this alliance, we plan to develop a device that automates preparing work for making piece and biochemical analysis of human hair by the exposome platform of LINUS.

3. Details of business alliance partner.

(1) Name	Linus Biotechnology, Inc. (URL : https://linusbio.com/)	
(2) Head Office	101 6th Avenue, New York, NY, 10013, USA	
(3) Name of representative	Dr. Manish Arora, C.E.O.	
(4) Business	<p>Linus Biotechnology, Inc. is a patient-centric, precision exposome medicine company headquartered in New York, NY.</p> <p>Originating from the world's leading exposome laboratory at Mount Sinai Health System, and it has developed a technology platform that builds on breakthroughs in exposome sequencing.</p>	
(5) Paid up capital	US\$ 14,700,000.00	
(6) Date of establishment	Mar. 31, 2021	
(7) Major shareholders and ratio	<p>Icahn School of Medicine at Mt. Sinai: 25%</p> <p>Dr. Manish Arora: 16%</p> <p>Great Point Ventures Innovation Fund III, LP : 16%</p> <p>Bow Capital Fund II, LP : 16%</p> <p>Dr. Christine Austin: 8%</p> <p>Dr. Paul Curtin: 8%</p>	
(8) Relationship between the listed company and the relevant company.	Capital relationship	None
	Personnel relationship	None
	Trade relationship	None
	Related party relationship	None
(9) Consolidated operating results and financial position of the relevant company for the last three years. (US\$)		
Financial year	9 months ended Dec.31, 2021	Financial year ending Dec..31, 2022 (forecast)
Consolidated net assets	-\$750,836.00	\$13,326,212.00
Consolidated total assets	\$1,077,259.00	\$14,062,181.00
Consolidated net assets per share	-\$0.043	\$0.424
Consolidated sales	\$0.00	\$422,533.00
Consolidated operating income	-\$750,835.00	-\$3,377,043.00
Consolidated ordinary income	-\$750,835.00	-\$3,296,651.00
Profit attributable to owners of parent	Not applicable	Not applicable
Consolidated net income per share	-0.043	\$0.105
Dividend per share	\$0.00	\$0.00

Major customers: Johnson & Johnson, Novozymes A/S, F. Hoffmann-La Roche, Ltd.

4. Schedule

Signing date of LOI: Dec. 8, 2022 (US time)

5. Future Prospects

Although the impact of this matter on the Company's consolidated results for the fiscal year ending March 31, 2023 will be minor, we believe that it will contribute to the improvement of the Group's future business results.

In addition, depending on the status of this discussion, we will disclose information in a timely manner when we judge it that it will be beneficial to shareholders and investors.

«Reference»

1. About "Autism Improvement Program" by LINUS.

- (1) The company is an independent startup venture spun out from the Icahn School of Medicine at Mount Sinai, New York, USA, and is backed by Great Point Ventures, Bow Capital, and others. It is based in J Labs (New York), which is the innovation hub of Johnson & Johnson.
- (2) The LINUS's "Autism improvement program" has been designated as a breakthrough device by the U.S. FDA.

END